Skip to content
Peptigraph home

CJC-1295 and Tesamorelin Together: What Is Known

CJC-1295 and Tesamorelin taken together: what each one is, how each is regulated, and what is known about combining them.

Medically reviewed by Juan Pablo Frías, MD · · DisclosureUpdated
GHRH analogNot FDA approved · research chemicalCJC-1295CJC-1295, a GHRH analog; in healthy adults a single injection produced dose-dependent rises in mean plasma GH of 2- to 10-fold and in IGF-I of 1.5- to 3-fold.[5]Growth hormoneGHRH analogFDA approved (Egrifta)TesamorelinFDA-approved GHRH analog (Egrifta) for excess abdominal fat in HIV-associated lipodystrophy; visceral fat fell 15.2% versus a 5.0% rise with placebo in a randomized trial.[15]Growth hormone
Interaction notes

Timing, interactions and safety

Evidence for the combination

No studies tested these together (PubMed search: 15 results, 2 Oct 2026).

CJC-1295 is not FDA approved, and we have no sourced data on combining it with Tesamorelin.
Each component

Side by side

Showing 7 of 13 fields where the two differ. Class, Category, PCAC vote, Jul 2026, WADA, Anti-doping detection, Evidence strength are the same or both unknown.

FieldCJC-1295Tesamorelin
Also calledCJC, mod GRF, GRF 1-29tesa, Egrifta
FDA statusNot FDA approved · research chemicalFDA approved (Egrifta)
Half-lifeNo published half-life foundPubMed search, 11 Oct 202611 minutessubcutaneous (EGRIFTA WR 1.28 mg) · FDA label (Egrifta WR)
Human studies we summarised4 human (1 randomized or controlled) of 7 summarised12 human (11 randomized or controlled) of 16 summarised
Typical study doses
Vial sizes sold2 mg, 5 mg, 10 mg2 mg, 5 mg, 10 mg, 20 mg
Named in FDA warning letters, 2026Not in the letters we trackYes (24 Aug 2026)
Related tools

CJC-1295 vs Tesamorelin

Choosing between the two rather than combining them? The comparison lines them up field by field.

Open the comparison

Both are GHRH analogues, built for very different durations

After a single injection in healthy adults, the estimated half-life of CJC-1295 was 5.8-8.1 days.[5]

The CJC-1295 used in trials binds permanently to albumin after injection.[6]

Tesamorelin's label gives a half-life of 11 minutes in healthy subjects after a single injection of the WR formulation.[10]

Converted to a common unit, CJC-1295's reported half-life is about 760 to 1060 times tesamorelin's.

Calculated from cjc half life days 5.8, 8.1; tesamorelin half life minutes 11. Formula: CJC hours = days x 24 = 139.2 to 194.4 h; tesamorelin hours = 11 / 60 = 0.183 h; ratio = 139.2 / 0.183 = 759 and 194.4 / 0.183 = 1060

What each shows in people

In healthy adults, a single CJC-1295 injection raised mean growth hormone 2- to 10-fold for 6 days or more, and IGF-I 1.5- to 3-fold.[5]

A trial randomised 412 patients with HIV and abdominal fat to daily tesamorelin or placebo for 26 weeks, with visceral fat on CT as the primary endpoint.[15]

In a pulsatility study, CJC-1295 raised trough GH 7.5-fold and IGF-I 45%.[6]

FDA, label and sport status

FDA says it has identified serious adverse events associated with CJC-1295, including increased heart rate and a systemic vasodilatory reaction.[17]

Tesamorelin's label warns that it raises IGF-1 and says the effects of prolonged elevation are unknown.[10]

WADA lists both in the same prohibited GHRH class.[2]

A PubMed search on 2 Oct 2026 for CJC-1295 together with tesamorelin matched 15 records; none is recorded as a trial of the two combined.

Calculated from pubmed query ("CJC-1295"[tiab] OR CJC1295[tiab]) AND (tesamorelin[tiab] OR Egrifta[tiab] OR TH9507[tiab] OR "TH-9507"[tiab]); records matched 15; search date 2026-10-02. Formula: records_matched = PubMed count recorded in combinations.json for the query on search_date

Common questions

CJC-1295 vs tesamorelin: what is the difference?

Tesamorelin's label gives a half-life of minutes, while the estimated half-life of CJC-1295 in healthy adults was 5.8-8.1 days.[5]

Can you take CJC-1295 and tesamorelin together?

No trial in the cached results has combined them. WADA lists both under the same GHRH class.[2]

Sources

  1. 1FDA warning letters to five research-peptide sellersFDA warning letter (NuScience Peptides; 1 of 5) · 2026fda.govAccessed 2 Oct 2026
  2. 2World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
  3. 3An antibody-free, ultrafiltration-based assay for the detection of growth hormone-releasing hormones in urine at low pg/mL concentrations using nanoLC-HRMS/MS.Journal of pharmaceutical and biomedical analysis · 2022PMID 35298973Accessed 2 Oct 2026
  4. 4Advances in the detection of growth hormone releasing hormone synthetic analogs.Drug testing and analysis · 2021PMID 34665524Accessed 2 Oct 2026
  5. 5Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.The Journal of clinical endocrinology and metabolism · 2006PMID 16352683Accessed 2 Oct 2026
  6. 6Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog.The Journal of clinical endocrinology and metabolism · 2006PMID 17018654Accessed 2 Oct 2026
  7. 7Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse.American journal of physiology. Endocrinology and metabolism · 2006PMID 16822960Accessed 2 Oct 2026
  8. 8PubMed search: ("CJC-1295"[tiab] OR CJC1295[tiab]) (33 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  9. 9PubMed search: ("CJC-1295"[tiab] OR CJC1295[tiab]) AND (half-life[tiab] OR pharmacokinetic*[tiab]) (7 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  10. 10EGRIFTA WR (TESAMORELIN) KIT [THERATECHNOLOGIES INC.]FDA label (Egrifta WR), DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
  11. 11The effect of growth hormone-releasing hormone on cognition and brain connectivity in adults with cognition ranging from normal to mild cognitive impairment.eNeurologicalSci · 2026PMID 42382101Accessed 2 Oct 2026
  12. 12Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial.The lancet. HIV · 2019PMID 31611038Accessed 2 Oct 2026
  13. 13The Growth Hormone Releasing Hormone Analogue, Tesamorelin, Decreases Muscle Fat and Increases Muscle Area in Adults with HIV.The Journal of frailty & aging · 2019PMID 31237318Accessed 2 Oct 2026
  14. 14PubMed search: ("CJC-1295"[tiab] OR CJC1295[tiab]) AND (tesamorelin[tiab] OR Egrifta[tiab] OR TH9507[tiab] OR "TH-9507"[tiab])PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  15. 15Metabolic effects of a growth hormone-releasing factor in patients with HIV.The New England journal of medicine · 2007PMID 18057338Accessed 2 Oct 2026
  16. 16PubMed search: ("CJC-1295"[tiab] OR CJC1295[tiab]) AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab] OR "case report"[pt]) (11 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
  17. 17Official web pageOfficial web page · web page

Found an error? Report a correction.